作者：
John J,Kelly [1]
;
Dale,Tranter [2]
;
Els,Pardon [3]
;
Gamma,Chi [4]
;
Holger,Kramer [1]
;
Lotta,Happonen [5]
;
Kelly M,Knee [6]
;
Jay M,Janz [7]
;
Jan,Steyaert [7]
;
Christine,Bulawa [3]
;
Ville O,Paavilainen [4]
;
Juha T,Huiskonen [7]
;
Wyatt W,Yue [2]
作者单位：
Centre for Medicines Discovery, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
[1]
Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
[2]
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
[3]
VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium.
[4]
Biological Mass Spectrometry and Proteomics Facility, MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK.
[5]
Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
[6]
Pfizer Rare Disease Research Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, MA, USA.
[7]
Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland. juha.huiskonen@helsinki.fi.
[8]
Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland. juha.huiskonen@helsinki.fi.
[9]
Division of Structural Biology, Wellcome Centre for Human Genetics, Roosevelt Drive, University of Oxford, Oxford, UK. juha.huiskonen@helsinki.fi.
[10]
Centre for Medicines Discovery, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. wyatt.yue@cmd.ox.ac.uk.
[11]
Biosciences Institute, Medical School, Newcastle University, Newcastle upon Tyne, UK. wyatt.yue@cmd.ox.ac.uk.
[12]
DOI
10.1038/s41594-022-00755-1
PMID
35449234
发布时间
2023-03-22
换一批
换一批
